Biosig Technologies, Inc. (NASDAQ:STEX – Get Free Report) CIO Mitchell Young Williams sold 72,689 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $0.72, for a total transaction of $52,336.08. Following the completion of the sale, the executive owned 2,885,814 shares of the company’s stock, valued at $2,077,786.08. This trade represents a 2.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Biosig Technologies Trading Up 3.6%
Shares of STEX opened at $0.71 on Friday. The firm’s 50-day moving average is $0.82 and its two-hundred day moving average is $1.16. Biosig Technologies, Inc. has a twelve month low of $0.66 and a twelve month high of $7.44. The firm has a market capitalization of $83.27 million, a P/E ratio of -0.08 and a beta of 2.01.
Biosig Technologies (NASDAQ:STEX – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $0.15 million for the quarter.
Analyst Ratings Changes
STEX has been the subject of several research reports. Wall Street Zen raised Biosig Technologies from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Biosig Technologies in a report on Wednesday, July 29th. Finally, Needham & Company LLC dropped their price target on Biosig Technologies to $4.00 and set a “buy” rating for the company in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Biosig Technologies presently has a consensus rating of “Hold” and a consensus target price of $4.00.
Read Our Latest Report on STEX
About Biosig Technologies
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Featured Stories
- Five stocks we like better than Biosig Technologies
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Biosig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
